An Independence, Louisiana woman filed a Zofran lawsuit last month against GlaxoSmithKline, the makers of the medication, after a routine prenatal medical exam showed that her baby had developed serious heart defects.
According to the lawsuit, filed in the U.S. District Court of the Eastern District of Louisiana on June 26, the plaintiff was prescribed Zoloft during the first trimester of her pregnancy, in order to help her with ongoing bouts of morning sickness. She continued to take Zofran throughout the third trimester of her pregnancy, as directed by her physician.
Although Zofran is only approved for cancer patients who are undergoing treatments that cause nausea and vomiting, the drug has been promoted and prescribed for “off-label” use for pregnant women experiencing morning sickness.
The plaintiff’s unborn infant was diagnosed with “several congenital heart defects,” including an atrial septal defect. According to a Zofran attorney, the type of defects the infant has makes the case notable and provides more proof that Zofran can cause atrial septal defects, as noted in a study performed on Zofran by Denmark scientists.
“Many of the lawsuits filed thus far have been brought in relation to heart defects, ut this claim is notable for involving an atrial septal defect. A team of researchers in Denmark found that women prescribed Zofran during the first trimester were more than twice as likely to have babies with ASD (atrial septal defect).”
When the plaintiff’s infant son was born, he was diagnosed with a severe condition known as partial anomalous pulmonary venous return (PAPVR). This type of birth defect is marked by veins that transfer blood to the lungs developing on the wrong side of the body. The baby has already had to undergo two major surgeries to help correct his medical problems.
Since Zofran has never been approved by the U.S. Food and Drug Administration (FDA) for use by pregnant women, the plaintiff is suing GlaxoSmithKline, the maker of the medication. The complaint indicates that GlaxoSmithKline illegally promoted the use of Zofran for pregnant women, touting it as “safe and effective” in combating morning sickness.
In addition, the plaintiff claims that for numerous years, GlaxoKlineSmith was provided with numerous reports that show evidence of the heightened risk of birth defects should pregnant women take Zofran. Allegedly, the company willfully ignored the provided evidence and continued to promote Zofran to pregnant women, even offering kickbacks to the physicians who prescribed the medication to their pregnant patients.
The plaintiff’s lawsuit also asserts that GlaxoKlineSmith ignored “internal analyses” reports that showed the risks of unborn babies associated with Zofran developing a myriad of birth defects, some of which can lead to infant death.
This lawsuit is just one among numerous cases that have recently been filed against GlaxoKlineSmith. As more and more information becomes available concerning the hidden risks of birth defects, the number of complaints against the company are expected to rise.
Some of the numerous birth defects associated with Zofran include:
- Cleft lip and cleft palate
- Heart Defect
- Developmental delays
- Kidney defects
- Cranial problems
- Hearing and vision problems
- Jaundice, and more
Keep in mind that if you were prescribed Zofran during pregnancy and your baby has developed a birth defect, you have the legal right to file a Zofran lawsuit against the responsible party. You may be entitled to compensation for medical costs and expenses, pain, suffering, lost wages, and more.
For additional, in-depth information on Zofran lawsuits and to see if you may qualify for compensation, refer to our article, Zofran Lawsuits.